Vericel (VCEL) Expected to Announce Earnings on Thursday

Vericel (NASDAQ:VCEL) is projected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of $0.31 per share and revenue of $76.47 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Vericel Stock Performance

Vericel stock opened at $52.33 on Tuesday. The business’s 50-day simple moving average is $57.56 and its two-hundred day simple moving average is $51.70. The company has a market cap of $2.58 billion, a PE ratio of 872.31 and a beta of 1.72. Vericel has a fifty-two week low of $39.12 and a fifty-two week high of $63.00.

Analyst Ratings Changes

A number of equities research analysts recently commented on VCEL shares. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Vericel in a research report on Wednesday, January 15th. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, December 24th. Stephens reissued an “overweight” rating and set a $65.00 target price on shares of Vericel in a report on Wednesday, January 15th. Canaccord Genuity Group boosted their target price on shares of Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Finally, Truist Financial increased their price target on Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Vericel has a consensus rating of “Moderate Buy” and a consensus target price of $63.14.

Insider Buying and Selling

In other news, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the sale, the director now directly owns 26,595 shares in the company, valued at $1,662,187.50. This trade represents a 8.59 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jonathan Mark Hopper sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $58.72, for a total value of $587,200.00. Following the completion of the transaction, the insider now directly owns 58,371 shares of the company’s stock, valued at $3,427,545.12. The trade was a 14.63 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,100 shares of company stock valued at $1,206,072. Corporate insiders own 5.20% of the company’s stock.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.